MCID: NDL021
MIFTS: 49

Nodular Lymphocyte Predominant Hodgkin Lymphoma

Categories: Cancer diseases, Immune diseases, Blood diseases, Rare diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards integrated aliases for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 55 69
Nlphl 55

Characteristics:

Orphanet epidemiological data:

55
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to lymphoma, hodgkin, classic and lymphoma, and has symptoms including hyperhidrosis, pruritus and splenomegaly. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are NF-kappaB Signaling and Transcriptional misregulation in cancer. The drugs Vinblastine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cellular

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 32.8 BCL6 PAX5 PTPRC
2 lymphoma 31.1 BCL6 CCND1 PAX5
3 b-cell lymphomas 30.5 BCL6 CCND1 PAX5
4 diffuse large b-cell lymphoma 30.1 BCL6 CCND1 PAX5
5 lymphoma, non-hodgkin, familial 29.0 BCL6 CCND1 PAX5 PTPRC
6 hodgkin's granuloma 10.6
7 t-cell/histiocyte rich large b cell lymphoma 10.4
8 heart lymphoma 10.2 BCL6 PTPRC
9 testicular lymphoma 10.2 BCL6 PTPRC
10 composite lymphoma 10.2 BCL6 PAX5
11 intraocular lymphoma 10.2 BCL6 PAX5
12 colon lymphoma 10.2 BCL6 PTPRC
13 primary central nervous system lymphoma 10.2 BCL6 PAX5
14 plasmablastic lymphoma 10.2 BCL6 PTPRC
15 epidural neoplasm 10.2 BCL6 PTPRC
16 multicentric castleman disease 10.2 BCL6 PAX5
17 lymphosarcoma 10.2 BCL6 PTPRC
18 lymphatic system cancer 10.2 BCL6 PTPRC
19 mediastinal malignant lymphoma 10.1 BCL6 PAX5
20 lung lymphoma 10.1 BCL6 PAX5
21 mediastinal gray zone lymphoma 10.1 BCL6 PAX5
22 peripheral t-cell lymphoma 10.1
23 progressive transformation of germinal centers 10.1
24 chops syndrome 10.1
25 hodgkin's lymphoma, lymphocytic depletion 10.1 PAX5 PTPRC
26 splenic marginal zone lymphoma 10.1 BCL6 PAX5
27 mature b-cell neoplasm 10.1 BCL6 PTPRC
28 lymphoblastic lymphoma 10.1 BCL6 PTPRC
29 myeloid sarcoma 10.1 PAX5 PTPRC
30 marginal zone b-cell lymphoma 10.0 BCL6 CCND1
31 lymphoma, mucosa-associated lymphoid type 10.0 BCL6 CCND1
32 sarcoma 10.0
33 fibrosis of extraocular muscles, congenital, 1 10.0
34 leiomyoma 10.0
35 kaposi sarcoma 10.0
36 cervicitis 10.0
37 li-fraumeni syndrome 10.0
38 polyradiculopathy 10.0
39 anemia, autoimmune hemolytic 10.0
40 adult lymphoma 10.0
41 thyroiditis 10.0
42 mediastinitis 10.0
43 li-fraumeni syndrome 2 10.0
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
45 warthin tumor 10.0
46 ring chromosome y syndrome 10.0
47 hemolytic anemia 10.0
48 primary mediastinal large b-cell lymphoma 10.0
49 hepatitis 10.0
50 burkitt lymphoma 9.9 BCL6 PAX5

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

55 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000975
2 pruritus 55 31 occasional (7.5%) Occasional (29-5%) HP:0000989
3 splenomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0001744
4 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
5 fever 55 31 frequent (33%) Frequent (79-30%) HP:0001945
6 anorexia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002039
7 hepatomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0002240
8 lymphadenopathy 55 31 hallmark (90%) Very frequent (99-80%) HP:0002716
9 immunodeficiency 55 31 hallmark (90%) Very frequent (99-80%) HP:0002721
10 breast carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0003002
11 abnormality of bone marrow cell morphology 55 31 occasional (7.5%) Occasional (29-5%) HP:0005561
12 b-cell lymphoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0012191
13 fatigue 55 31 occasional (7.5%) Occasional (29-5%) HP:0012378
14 lymphoma 55 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CCND1 PDCD1 PTPRC

MGI Mouse Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
2 growth/size/body region MP:0005378 9.93 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
3 hematopoietic system MP:0005397 9.91 PTPRC BCL6 CCND1 IGF1 PAX5 PDCD1
4 endocrine/exocrine gland MP:0005379 9.88 BCL6 CCND1 IGF1 PDCD1 PTPRC
5 immune system MP:0005387 9.88 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
6 mortality/aging MP:0010768 9.85 BCL6 CCND1 IGF1 PAX5 PDCD1 PTPRC
7 neoplasm MP:0002006 9.72 CCND1 IGF1 PAX5 PDCD1 PTPRC
8 nervous system MP:0003631 9.65 CCND1 PTPRC IGF1 PAX5 PDCD1
9 normal MP:0002873 9.55 BCL6 CCND1 IGF1 PAX5 PTPRC
10 respiratory system MP:0005388 9.35 BCL6 CCND1 IGF1 PDCD1 PTPRC
11 skeleton MP:0005390 9.02 PTPRC CCND1 IGF1 PAX5 PDCD1

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Drugs for Nodular Lymphocyte Predominant Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 4,Phase 2 865-21-4 241903 13342
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3 50-18-0, 6055-19-2 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 glucocorticoids Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 Hormone Antagonists Phase 4,Phase 3
10 Hormones Phase 4,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Peripheral Nervous System Agents Phase 4,Phase 3
13 Antiemetics Phase 4,Phase 3
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3
16 Antimitotic Agents Phase 4,Phase 3,Phase 2
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3
18 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2
19 Autonomic Agents Phase 4,Phase 3
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Prednisolone acetate Phase 4
22 Methylprednisolone acetate Phase 4
23 Methylprednisolone Hemisuccinate Phase 4
24 Neuroprotective Agents Phase 4
25 Prednisolone hemisuccinate Phase 4
26 Prednisolone phosphate Phase 4
27 Protective Agents Phase 4
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
29
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
30
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
31
Etoposide Approved Phase 3 33419-42-0 36462
32
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
33
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
34
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 44424639 60780
35
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
36
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
37
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
38
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
39
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
40
Doxil Approved June 1999 Phase 3 31703
41 Podophyllotoxin Phase 3 518-28-5
42
Cortisone Phase 3 53-06-5 222786
43 Dexamethasone acetate Phase 3 1177-87-3
44 Isophosphamide mustard Phase 3,Phase 2 0
45
protease inhibitors Phase 3
46 Adjuvants, Immunologic Phase 3,Phase 2
47 Topoisomerase Inhibitors Phase 3
48 HIV Protease Inhibitors Phase 3
49 Dermatologic Agents Phase 3
50 Ophthalmic Solutions Phase 3

Interventional clinical trials:

(show all 15)

# Name Status NCT ID Phase Drugs
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
4 Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Completed NCT01187303 Phase 2 Ofatumumab
5 Rituximab in Treating Patients With Hodgkin's Lymphoma Completed NCT00003820 Phase 2 Rituximab
6 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2 ifosfamide;bortezomib;vinorelbine tartrate
7 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2 panobinostat;lenalidomide
8 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2 vorinostat
9 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. Completed NCT01022996 Phase 2 Everolimus (RAD001)
10 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Recruiting NCT02626884 Phase 2 Ibrutinib
11 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2 gemcitabine hydrochloride;bendamustine hydrochloride
12 Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Terminated NCT00288067 Phase 1, Phase 2 fenretinide;rituximab
13 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
14 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
15 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157

Search NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

38
B Cells, T Cells, Bone Marrow, Bone, Breast, Lymph Node, Monocytes

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 153)
# Title Authors Year
1
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29309302 )
2018
2
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. ( 28971503 )
2018
3
Coping With Knife: Postoperative Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29413265 )
2018
4
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 29401099 )
2018
5
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127. ( 29351228 )
2018
6
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. ( 29222274 )
2017
7
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. ( 29230339 )
2017
8
J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. ( 28851661 )
2017
9
Cyclin D1 expression and polysomy in lymphocyte-predominant cells of nodular lymphocyte-predominant Hodgkin lymphoma. ( 28038705 )
2017
10
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28737231 )
2017
11
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Progressive Transformation of Germinal Centers. ( 29348956 )
2017
12
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation. ( 28902083 )
2017
13
T-cell rosettes in nodular lymphocyte-predominant Hodgkin lymphoma. ( 28183747 )
2017
14
Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 28522441 )
2017
15
Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Real-world Case Series of Consecutive Patients Treated by a Single Multidisciplinary Team in the East of England From 1999 to 2015. ( 28935378 )
2017
16
GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. ( 28877074 )
2017
17
Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data. ( 28737250 )
2017
18
Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation? ( 28369705 )
2017
19
Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. ( 27998726 )
2017
20
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups. ( 28220934 )
2017
21
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. ( 28233899 )
2017
22
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. ( 28802087 )
2017
23
Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma. ( 26712878 )
2016
24
A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. ( 27708232 )
2016
25
Atypical variants of nodular lymphocyte predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. ( 27816718 )
2016
26
A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. ( 26732883 )
2016
27
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. ( 26762971 )
2016
28
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. ( 26872637 )
2016
29
An unusual clinical and pathological presentation of a nodular lymphocyte predominant Hodgkin lymphoma ("Poppema Lennert" lymphoma). ( 27532537 )
2016
30
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. ( 26837698 )
2016
31
Nodular Lymphocyte Predominant Hodgkin Lymphoma Presenting with Unilateral Orbital Involvement. ( 27015240 )
2016
32
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group. ( 26996288 )
2016
33
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma. ( 26913966 )
2016
34
A case of composite classical and nodular lymphocyte predominant Hodgkin lymphoma with progression to diffuse large B-cell non-Hodgkin lymphoma: Diagnostic difficulty in fine-needle aspiration cytology. ( 27888658 )
2016
35
Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Thyroid. ( 28044111 )
2016
36
Nodular lymphocyte-predominant Hodgkin lymphoma. ( 27496311 )
2016
37
Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. ( 26658840 )
2016
38
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. ( 27999289 )
2016
39
Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations. ( 25929348 )
2015
40
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. ( 26430172 )
2015
41
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma? ( 26022927 )
2015
42
Characteristics and outcomes of patients with nodular lymphocyte-predominant hodgkin lymphoma versus those with classical hodgkin lymphoma: a population-based analysis. ( 25863756 )
2015
43
Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma. ( 26410017 )
2015
44
Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Warthin Tumor of the Parotid Gland: A Case Report and Literature Review. ( 26169920 )
2015
45
Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. ( 26685097 )
2015
46
Management of nodular lymphocyte predominant hodgkin lymphoma in the modern era. ( 25863755 )
2015
47
Incidence, management and outcome of high grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. ( 25715900 )
2015
48
Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. ( 26149294 )
2015
49
Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. ( 26538004 )
2015
50
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. ( 26240235 )
2015

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.33 BCL6 IGF1 PDCD1
2 humoral immune response GO:0006959 8.96 PAX5 PDCD1
3 positive regulation of B cell proliferation GO:0030890 8.62 BCL6 PTPRC

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....